WAVEMAN · COMPANY

TNDM · Tandem Diabetes Care Inc

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

TNDM

Name: TANDEM DIABETES CARE INC (TNDM) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

TANDEM DIABETES CARE INC

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001438133

CONGRESS · 2FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$4.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

148

13F, latest reported quarter

REVENUE GROWTH

+7.9%

XBRL, annual

NET MARGIN

-20.2%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$4.3K over 180 days

more than 69% of Medical Devices

CONGRESS

2 members bought in the last year

more than 81% of Medical Devices

FUNDS

148 funds added or opened last quarter

more than 69% of Medical Devices

REVENUE

+7.9% year over year

below 51% of Medical Devices

MARGIN

-20.2% net margin

below 60% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

148 funds added or opened positions in the latest 13F quarter, of 275 holders.

2 members of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +60.9%

+60.9%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $4.3K sold by insiders over 180 days, 148 funds added last quarter, 2 Congress member(s) bought in 12 months, $2.9K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, TANDEM DIABETES CARE INC insiders sold a net $4.3K of stock across 118 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Novara Mark David

EVP & CHIEF COMMERCIAL OFFICER

SELL

2026-03-17

187.0

$4.3K

Novara Mark David

EVP & CHIEF COMMERCIAL OFFICER

SELL

2026-03-05

2.0

$46

Sheridan John F

PRESIDENT & CEO

BUY

2025-08-11

10,000.0

$102.3K

Vosseller Leigh

EVP & CHIEF FINANCIAL OFFICER

BUY

2025-08-08

13,720.0

$149.4K

Kyrillos Jean-Claude

EVP & Chief Operating Officer

BUY

2025-03-07

10,538.0

$190.9K

118 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 113 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

11,583,125.0 sh

$174.8M

Sessa Capital IM, L.P.

5,100,000.0 sh

$77.0M

VANGUARD PORTFOLIO MANAGEMENT LLC

4,299,667.0 sh

$64.9M

First Light Asset Management, LLC

3,383,553.0 sh

$51.1M

VANGUARD CAPITAL MANAGEMENT LLC

3,096,536.0 sh

$46.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

MARK NOVARA

FILED 2026-08-18

$2.9K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Meridian Small Cap Growth Fund

$5.3M POSITION · AS OF 2026-03-31

2.2%

Meridian Growth Fund

$9.5M POSITION · AS OF 2026-03-31

2.0%

Global X HealthTech ETF

$574.7K POSITION · AS OF 2026-02-28

1.6%

State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF

$2.0M POSITION · AS OF 2026-03-31

1.5%

WESTWOOD ALTERNATIVE INCOME FUND

$2.0M POSITION · AS OF 2026-04-30

1.3%

Driehaus Micro Cap Growth Fund

$4.9M POSITION · AS OF 2026-03-31

1.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 16 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

1 ACTIVE

What changed recently

PS230005 Control-IQ 1.5 Post-Approval Study

2026-09-02 · Active Not Recruiting → Completed

—

Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in Peopl

2026-09-01 · Active Not Recruiting → Completed

Not applicable

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · John F. Sheridan

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$6.9M

$2.9M

$2.0M

-77%

-1%

2024

$8.5M

$6.8M

$1.9M

-40%

+5%

2023

$4.7M

$1.5M

-50%

+6%

2022

$6.4M

-$8.3M

$1.7M

-25%

-0%

2021

$5.7M

$16.4M

$1.6M

+153%

+25%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$1.0B	$940.2M	$747.7M	$801.2M
GROSS PROFIT	$546.0M	$489.6M	$367.7M	$413.0M
OPERATING INCOME	$-187.3M	$-99.1M	$-233.2M	$-92.8M
NET INCOME	$-204.7M	$-96.0M	$-222.6M	$-94.6M
EPS (DILUTED)	-3.04	-1.47	-3.43	-1.47
OPERATING CASH FLOW	$-9.7M	$24.2M	$-31.8M	$50.5M
CASH	$90.6M	$69.2M	$58.9M	$172.5M
LONG-TERM DEBT	$310.0M	$308.3M	$285.0M	—
BUYBACKS	$0	$30.0M	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE